Neuroinflammation is a key component of stroke pathology and involves the activation of immune cells such as microglia and astrocytes, and the release of inflammatory molecules such as cytokines and chemokines. Antibodies that target components of the neuroinflammatory pathway can provide valuable insights into the underlying mechanisms of stroke and may also serve as potential therapeutic targets, thus developing targeted therapies that can modulate this response and improve outcomes for stroke patients.